Finance

Beta
Lists
XIN:FRA
Shandong Xinhua Pharmaceutical Ord Shs H
€0.62
+0.81%
(+0.0050) 1D
Jun 5, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for XIN...
Open
€0.62
High
€0.62
Low
€0.62
Mkt. cap
8.57B
Avg. vol.
9.00
Volume
0.00
52-wk high
€0.97
52-wk low
€0.62
No. of employees
7K
Open
€0.62
High
€0.62
Low
€0.62
Mkt. cap
8.57B
Avg. vol.
9.00
Volume
0.00
52-wk high
€0.97
52-wk low
€0.62
No. of employees
7K
News stories
From sources across the web
About Shandong Xinhua Pharmaceutical Ord Shs H
CEO-
Employees7.24K
FoundedNov 1943
Headquarters-
SectorPharmaceutical industry
Websitexhzy.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
2.21B
2.12B
1.99B
2.42B
Cost of goods sold
1.79B
1.70B
1.70B
1.98B
Cost of revenue
1.79B
1.70B
1.70B
1.98B
Research and development expenses
92.64M
97.68M
81.51M
95.47M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
191.66M
211.30M
197.11M
198.38M
Operating expense
314.41M
297.65M
313.15M
307.72M
Total operating expenses
2.10B
2.00B
2.01B
2.29B
Operating income
107.06M
121.85M
-17.39M
133.38M
Other non operating income
-6.25M
5.12M
-4.38M
-7.51M
EBT including unusual items
120.84M
42.47M
52.92M
118.63M
EBT excluding unusual items
107.14M
111.70M
-28.30M
118.92M
Income tax expense
5.31M
6.73M
13.52M
35.37M
Effective tax rate
4.40%
15.84%
25.56%
29.81%
Other operating expenses
21.80M
-12.15M
37.37M
13.91M
Net income
111.66M
32.46M
33.67M
83.90M
Net profit margin
5.05%
1.53%
1.69%
3.46%
Earnings per share
0.16
0.03
0.04
0.12
Interest and investment income
8.02M
103.84K
4.92M
1.50M
Interest expense
-10.50M
-7.31M
-13.67M
-8.45M
Net interest expenses
-2.49M
-7.21M
-8.75M
-6.95M
Depreciation and amortization charges
-
-
-
-
EBITDA
246.86M
256.56M
129.14M
279.91M
Gain or loss from assets sale
-1.71M
1.71M
-1.99M
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more